Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of JNJ-53718678 on Cardiac Repolarization in Healthy Adults
NCT03696459Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rilematovir in respiratory syncytial virus infection (RSV) (8 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Placebo-Corrected Change from Baseline in QT Interval Corrected for Heart Rate (QTc) at Day 1. Started Oct 2018; status: completed.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03696459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03696459.